ANI Pharmaceuticals presents preclinical data on Purified Cortrophin Gel use

ANI Pharmaceuticals (ANIP) announced new preclinical data on the use of Purified Cortrophin Gel in a mouse model of murine collagen-induced inflammatory arthritis. “In a preclinical model of murine collagen-induced arthritis, repository corticotrophin injection attenuated joint swelling in mice, and decreased inflammatory cytokine response without causing additional bone turnover, as compared to controls,” said Mary Pao, CMO of Rare Disease at ANI. “These data further expand our understanding of Cortrophin Gel’s mechanism of action.” The effect of repository corticotropin injection, when used as monotherapy, was evaluated using a mouse collagen-induced arthritis model to assess the inflammatory response and bone damage. Following CIA induction, mice received subcutaneous RCI, or vehicle control. RCI treatment had a significant dose dependent effect on attenuating CIA-induced joint swelling and clinical scores at both doses when compared to vehicle with the greatest effect at the 400 U/kg dose. Additionally, RCI treatment at the 400 U/kg dose resulted in a reduction in inflammatory cytokine response, but no disruption in immunoglobulin G formation and no additive bone loss. This research was led by Maripat Corr, MD, Professor of Medicine at the University of California San Diego, La Jolla, CA and Nancy Lane, MD, Distinguished Professor of Medicine and Rheumatology at the University of California Sacramento, Davis, CA.